U.S. markets closed

Khiron Life Sciences Corp. (KHRN.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.4750+0.0100 (+2.15%)
At close: 3:59PM EST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4650
Open0.4700
Bid0.4650 x 0
Ask0.4750 x 0
Day's Range0.4450 - 0.4800
52 Week Range0.3000 - 1.2000
Volume1,149,655
Avg. Volume420,059
Market Cap55.835M
Beta (5Y Monthly)2.01
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Benzinga

      Khiron Is Continuing To Grow Its Presence In Latin America

      A rising tide is lifting all ships in cannabis right now. The legalization of cannabis in several key states has increased industry excitement about the potential of the U.S. market, prompting shares of many cannabis stocks to rally hard. But the good news is not limited to just the U.S. Elsewhere, cannabis activity in major overseas markets are continuing to rise. Latin America (Latam)-based Khiron Life Sciences (OTCQX: KHRNF), a cannabis operator focused on the medical and health & wellness markets, recently reported more than 4,600 prescriptions filled in Latin America, including 1,300 for the month of October, a 130% increase from July. In all, the company reported that total monthly patient consultations at Khiron clinics increased to over 9,500 in October, surpassing pre-pandemic levels in February. This comes after the company experienced a significant drop due to the pandemic, with 4,500 patient consultations in April.While many aspects of daily life have resumed in the ensuing months, the company says a focus on telehealth is partially what led to the growth in total consults. Roughly 15% of patient consultations are now conducted virtually, according to the company. It's also the result of increased sales in newer markets. Khiron which was the first company to prescribe and sell medical cannabis in Colombia, has also recently become the first company to sell medical cannabis in Peru. And recent data show that the initial 4-week sales activity in the latter has surpassed the initial rate in the former. "We are seeing the positive impact of our highly focused sales model in the key Latam markets of Colombia and Peru with targeted strategies for distribution, education and patient growth," said Khiron CEO Alvaro Torres in a release. "We are leveraging our experience in Colombia, together with the adoption of timely digital tools, and as a result are achieving increasing sales activity in the Colombian market and positive rates of initial sales in Peru."The digital tools Torres referred to includes Dr. Zerenia, a fully integrated telehealth portal. The app has successfully rolled-out in Colombia with plans to expand its reach across Latam.In addition to Colombia and Peru, Khiron is also working to expand its Latam operations in Brazil and Uruguay, as well as continued growth in the EU market, where it already has a presence in the UK and Germany. See more from Benzinga * Click here for options trades from Benzinga * APIs Are The Secret Sauce Of Fintech * 13 International Companies Giving Public Investor Presentations This Week(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Khiron Launches Solar Panel Plant In Colombian Cannabis Facility
      Benzinga

      Khiron Launches Solar Panel Plant In Colombian Cannabis Facility

      Khiron Life Sciences (OTC: KHRNF) has installed the first solar panel plant in Tolima, Colombia for a cannabis production complex. The company teamed up with ReFeel, a renewable energy company, on the initiative. The park counts 2,600 solar panels, delivering an annual production of 700 kilowatt-hours.CO2 emission is expected to reduce by about 570 tons per year."This solar park will allow us to save energy costs and self-generate 40% of our energy need while reducing CO2 emissions by 570 tons per year," said Khiron Life Sciences CEO and Co-Founder Alvaro Torres. "This project is closely aligned with our higher purpose of positively impacting people's quality of life."Flavia Santoro, President of Procolombia, explained that the project not only allows diversifying energy generation, but it also reduces dependence on water."Additionally, it opens the new frontier to promote national development," he said. "We are committed to this from the Government and ProColombia to promote the arrival of new investments in the sector. "The Italian company ReFeel will be in charge of the maintenance and operation of the infrastructure.RELATED: UK's Sapphire Medical Funds First Cannabis Treatment, While Khiron Backs Colombia ClinicPhoto from press releaseSee more from Benzinga * UK's Sapphire Medical Funds First Cannabis Treatment, While Khiron Backs Colombia Clinic * Cannabis Stock Gainers And Losers From July 27, 2020 * Cannabis Stock Gainers And Losers From July 24, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • UK's Sapphire Medical Funds First Cannabis Treatment, While Khiron Backs Colombia Clinic
      Benzinga

      UK's Sapphire Medical Funds First Cannabis Treatment, While Khiron Backs Colombia Clinic

      Medical marijuana is gaining more traction in international health care systems.In one scenario, Sapphire Medical Foundation announced the first UK patient to be granted full cannabis medicine treatment funding. Also, Khirion Life Sciences announced the opening of the first medical marijuana clinic in Colombia.UK Funding Sapphire Medical Foundation will fund a patient's fibromyalgia and rheumatoid arthritis treatment for at least one year.The organization's aim is to decrease the economic barriers to access cannabis-based treatments. According to Health Europa, most medical marijuana patients in the UK receive their prescriptions from the private sector, with almost no reimbursement. This makes it unaffordable for a large number of potential-patients.The patient is a 38-year old teacher named Kirran. Her last name has not been disclosed."My pain stops me doing the career I love. I love teaching and being in the classroom, for me there is nothing more rewarding and satisfying," she said. "The foundation grant is a beacon of hope for me in amidst the darkness. It represents the hope that I won't always have to live my life like this, that one day I may be able to return to teaching, regain a social life, and be able to live my life instead of feeling my life is passing me by."England Rugby player George Kruis and Trustee of the Foundation praised the development."Sapphire Medical Foundation gives hope to patients who may benefit from cannabis-based medicines but are unable to afford the current cost of treatment," he said. "With further fundraising, we will help many more patients and I am glad to be a part of it."Colombia's Clinic Colombia's first medical marijuana clinic has been inaugurated. The objective is to treat neurological pathologies as Parkinson's disease, epilepsy, insomnia, chronic headaches, anxiety and depression.Khiron Life Sciences has invested approximately CA$10 million into this clinic based on northern Bogota.The 22,600 square-foot facility is expected to treat 65,000 patients per year.Patients from all regions of Colombia will be able to access the treatments offered by the medical center with the use of its virtual telemedicine platform."We have invested to offer a face-to-face and virtual healthcare model that combines traditional medicine with different complementary alternatives, oriented to the diagnosis, treatment and timely recovery of each patient, applying principles of integrative medicine, offering multidisciplinary care and therapeutic alternatives with medical cannabis for patients who require it, in order to improve their quality of life," Rayet Harb, head of the clinic stated on the press release photo via unsplashSee more from Benzinga * Cannabis Stock Gainers And Losers From July 27, 2020 * Cannabis Stock Gainers And Losers From July 24, 2020 * New York Senate Widens Marijuana Offense Release Terms(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.